<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304850</url>
  </required_header>
  <id_info>
    <org_study_id>9258-03</org_study_id>
    <secondary_id>2002-004</secondary_id>
    <nct_id>NCT00304850</nct_id>
  </id_info>
  <brief_title>Polyamine-free Diet to Prevent Post Surgery Hyperalgesia</brief_title>
  <acronym>PoLyDOL</acronym>
  <official_title>Efficacy of a Polyamine-free Diet Associated or Not With Ketamine on Early and Late Hyperalgesia After Breast Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Insurance CNP foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After surgery, sensitization and hyperexcitability of central nervous system result in acute
      and long lasting postoperative pain. It has been shown that N-methyl-D-aspartate (NMDA)
      receptors antagonist (such as ketamine) prevent this adverse neuroplasticity and potentiate
      analgesic drugs efficacy. Polyamines (putrescine, spermidine, spermine) are essential
      components of cells functioning and are also known as allosteric modulators of NMDA
      receptors. In animal studies, polyamine-free diet has confirmed these antinociceptive
      properties. This research aims at evaluating anti hyperalgesic properties of polyamine-free
      diet in women operated on breast cancer versus kétamine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentric, single blind study will enrol 160 women (18-75 years old) operated on
      tumorectomy and adenectomy (T1, T2, T3, N0, N1, M0) for breast cancer. Patients will be
      randomly assigned in a 2x2 factorial plan : Group 1 = control (n = 40) ; group 2 = ketamine
      group administered during and 48 hours after a standardized anesthesia (n = 40) ; group 3 =
      polyamine-free diet, 1 week and 72 hours after surgery (n = 40) ; group 4 : ketamine +
      polyamine-free diet (n = 40).

      The amount of morphine for the 24 first postoperative hours will be compared between each
      group as well as pain score, allodynia (Von Frey filaments) and hyperalgesia (algometer).
      Chronic pain occurrence (post-mastectomy pain syndrome) will be evaluated at 3 and 6 months
      using adequate questionnaire ( analgesic scale). Diet observance will be controlled
      preoperatively by a dosage of polyamines in circulating red cells blood.

      Polyamines deprivation and ketamine ability to reduce postoperative pain will be compared
      (isobolographic method). Anti-hyperalgesic properties of ketamine have already been
      demonstrated in urologic, orthopaedic and abdominal surgery. In case of additive or
      synergistic effect of a polyamine deprivation such a strategic could be helpful to achieve
      better postoperative rehabilitation in reducing chronic pain after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine requirement</measure>
    <time_frame>for the 24 postoperative hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity for the 4 days (and possibly at 7th day if the patient is still hospitalized) after surgery</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allodynia measurements</measure>
    <time_frame>inclusion, 1, 2, 4 and 7 ddays after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperesthesia measurements</measure>
    <time_frame>inclusion, 1, 2, 4 and 7 ddays after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic pain incidence</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late allodynia and/or hyperesthesia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of treatment</measure>
    <time_frame>Along each patient folow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>R+ / K+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>R+ / K-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>R- / K+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>R- /K-</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>polyamine-free diet</intervention_name>
    <description>Polyamine-free diet in the 7 days befor surgery</description>
    <arm_group_label>R+ / K+</arm_group_label>
    <arm_group_label>R+ / K-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine or placebo</intervention_name>
    <description>Peroperative and post operative (48h) ketamine injection</description>
    <arm_group_label>R+ / K+</arm_group_label>
    <arm_group_label>R+ / K-</arm_group_label>
    <arm_group_label>R- / K+</arm_group_label>
    <arm_group_label>R- /K-</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer (T1, T2, T3, N0, N1, M0)

          -  Age : 18 - 75

          -  Asa 1-3

          -  left or right tumorectomy with complete lymphadenectomy

          -  left or right complete mastectomy with complete lymphadenectomy

          -  complete lymphadenectomy within one week following simple tumorectomy

          -  informed consent signed

        Exclusion Criteria:

          -  inflammatory tumor requiring pre-operative radiotherapy

          -  previous history of total mastectomy or partial contralateral mastectomy

          -  chronic inflammatory disease treated by corticoids or NSAI

          -  chronic analgesic treatment

          -  anti-arrhythmic or anti-epileptic treatments

          -  morphinic treatment during the 7 days before surgery

          -  excessive alcohol consumption or addiction

          -  ketamine or neomycin contra-indication

          -  severe cardiovascular disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre MAURETTE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>DAR 3 -Pellegrin hospital-33076 Bordeaux - France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Genevieve CHENE, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>University hospital - 33076 Bordeaux - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CLCC-Institut Bergonie, service d'anesthésie réanimation, 229 cours de l'Argonne</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>département d'anesthésie-réanimation 3, hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLCC Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHParis Hôpital Pitié Salpétrière - Dépt. d'anesthésie réanimation</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLCC Réné Huguenin de Saint Cloud</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2006</study_first_submitted>
  <study_first_submitted_qc>March 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2006</study_first_posted>
  <last_update_submitted>December 24, 2009</last_update_submitted>
  <last_update_submitted_qc>December 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jean-Pierre LEROY / Clinical Research and Innovation Director</name_title>
    <organization>University Hospital, Bordeaux</organization>
  </responsible_party>
  <keyword>polyamines</keyword>
  <keyword>pain</keyword>
  <keyword>breast cancer</keyword>
  <keyword>mastectomy</keyword>
  <keyword>post operative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

